| Literature DB >> 32436421 |
Abstract
There are several situations such as medical emergencies and incidents involving mass casualties where drugs and antidotes have to be administered immediately along with other first aid at the site of the event. Self-administration by the affected person or by a companion is required as a life-saving measure. Autoinjector devices (AIDs) are useful for the rapid administration of drugs and antidotes and they can also be used by those who have not been medically trained. This makes them very convenient for emergency and mass casualty management. An AID has a drug cartridge with an embedded needle for subcutaneous or intramuscular injection, which is usually painless. The drugs are delivered slowly by the AID across a large area in the muscle, which increases the absorption and the drug effects are equal to that of intravenous administration. A variety of AIDs are available, such as atropine and pralidoxime for nerve agent poisoning, epinephrine for anaphylactic shock and allergy, diazepam for seizures, sumatriptan for migraine, amikacin for antibacterial treatment, buprenorphine for pain relief and monoclonal antibodies for a variety of diseases. This review describes the published peer-reviewed literature identified by online searches of journal databases.Entities:
Keywords: Autoinjector device; analgesic; anaphylaxis; antidotes; antimicrobial; drugs; migraine; monoclonal antibodies; nerve agent; seizures
Mesh:
Substances:
Year: 2020 PMID: 32436421 PMCID: PMC7243406 DOI: 10.1177/0300060520926019
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Figure 1.Examples of reusable autoinjectors with drug cartridges for emergency situations and mass casualty management. The colour version of this figure is available at: http://imr.sagepub.com.
Summary of the available autoinjector devices for subcutaneous (s.c.), intramuscular (i.m.) and intracorporeal (i.c.) administration of a range of drugs.
| Serial number | Autoinjector device and route | Clinical condition | Efficacy studies by countries | Preclinical or clinical studies |
|---|---|---|---|---|
| 1 | Atropine and an oxime, i.m. (pralidoxime, obidoxime, HI 6 and HLö 7) | Nerve agent poisoning | India, Israel, France, the Netherlands, Germany, Sweden, Czech Republic, UK, USA | Rat, guinea pig, rabbit, pig, dog, monkey, human |
| 2 | Diazepam i.m. | Seizures | Italy, USA | Human |
| 3 | Midazolam i.m. | Seizures | USA | Pig, human |
| 4 | Epinephrine i.m. | Anaphylaxis | Japan, Qatar, Saudi Arabia, Portugal, Spain, Greece, Bulgaria, Austria, France, Italy, Poland, Germany, Switzerland, the Netherlands, Finland, Sweden, UK, Mexico, Brazil, USA, Canada, Australia, | Human |
| 5 | Methotrexate s.c. | Rheumatoid arthritis | France, the Netherlands, Germany, USA | Human |
| 6 | Etanercept s.c. | Rheumatoid arthritis | France, Germany, Italy, Spain, UK | Human |
| 7 | Amikacin i.m. | Antibacterial | India | Rat, rabbit |
| 8 | Buprenorphine i.m. | Analgesic | India | Rat, rabbit |
| 9 | Naloxone i.m. | Opioid overdose | USA | Human |
| 10 | Ezetimibe s.c. | Hypercholesterolaemia | Switzerland, UK, USA | Human |
| 11 | Aviptadil and phentolamine i.c. | Erectile dysfunction | the Netherlands, UK | Human |
| 12 | Peginterferon β-1a Peginterferon β-1b s.c. | Multiple sclerosis | Germany, the Netherlands, Switzerland, Greece, Spain, Portugal, Italy, Romania, New Zealand, UK, USA, Canada | Human |
| 13 | Peginterferon α-2a s.c. | Hepatitis C | USA | Human |
| 14 | Thrombolytic agents αIIbβ3 and αVβ3 i.m. | Myocardial infarction | USA | Primates |
| 15 | Alirocumab s.c. | Hypercholesterolaemia | France, Finland, the Netherlands, UK, USA | Human |
| 16 | Evolocumab s.c. | Hypercholesterolaemia | Switzerland, UK, USA | Human |
| 17 | Belimumab s.c. | Systemic lupus erythematosus | UK, USA | Human |
| 18 | Adalimumab s.c. | Rheumatoid arthritis and joint and bowel disease | Republic of Korea, Poland, Germany, Belgium, the Netherlands, Switzerland, UK, USA, New Zealand | Human |
| 19 | Golimumab s.c. | Rheumatoid arthritis and ulcerative colitis | Italy, Poland, Romania, Germany, Belgium, UK, USA, Russia | Human |
| 20 | Sarilumab s.c. | Rheumatoid arthritis | France, USA, Russia | Human |
| 21 | Tocilizumab s.c. | Rheumatoid arthritis | Spain, Germany, Switzerland, UK, Brazil, Mexico, USA, Canada | Human |
| 22 | Sirukumab s.c. | Rheumatoid arthritis | the Netherlands, USA | Human |
| 23 | Certolizumab pegol s.c. | Rheumatoid arthritis and psoriasis | Belgium, UK, USA | Human |
| 24 | Secukinumab s.c. | Psoriasis | China, Australia, Spain, Estonia, France, Germany, Czech Republic, Switzerland, UK, USA, Canada | Human |
| 25 | Ixekizumab s.c. | Psoriasis | Singapore, UK, USA | Human |
| 26 | Omalizumab s.c. | Anaphylaxis | Italy, Poland, UK, USA | Human |
| 27 | Canakinumab s.c. | Inflammatory diseases | India, Switzerland, USA | Human |